The Neuronal Actions of Leptin and the Implications for Treating Alzheimer's Disease

It is widely accepted that the endocrine hormone leptin controls food intake and energy homeostasis via activation of leptin receptors expressed on hypothalamic arcuate neurons. The hippocampal formation also displays raised levels of leptin receptor expression and accumulating evidence indicates th...

Full description

Saved in:
Bibliographic Details
Main Authors: Kirsty Hamilton (Author), Jenni Harvey (Author)
Format: Book
Published: MDPI AG, 2021-01-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_3d7de7ffd6cc4e788a1fc6772e06a3b9
042 |a dc 
100 1 0 |a Kirsty Hamilton  |e author 
700 1 0 |a Jenni Harvey  |e author 
245 0 0 |a The Neuronal Actions of Leptin and the Implications for Treating Alzheimer's Disease 
260 |b MDPI AG,   |c 2021-01-01T00:00:00Z. 
500 |a 10.3390/ph14010052 
500 |a 1424-8247 
520 |a It is widely accepted that the endocrine hormone leptin controls food intake and energy homeostasis via activation of leptin receptors expressed on hypothalamic arcuate neurons. The hippocampal formation also displays raised levels of leptin receptor expression and accumulating evidence indicates that leptin has a significant impact on hippocampal synaptic function. Thus, cellular and behavioural studies support a cognitive enhancing role for leptin as excitatory synaptic transmission, synaptic plasticity and glutamate receptor trafficking at hippocampal Schaffer collateral (SC)-CA1 synapses are regulated by leptin, and treatment with leptin enhances performance in hippocampus-dependent memory tasks. Recent studies indicate that hippocampal temporoammonic (TA)-CA1 synapses are also a key target for leptin. The ability of leptin to regulate TA-CA1 synapses has important functional consequences as TA-CA1 synapses are implicated in spatial and episodic memory processes. Moreover, degeneration is initiated in the TA pathway at very early stages of Alzheimer's disease, and recent clinical evidence has revealed links between plasma leptin levels and the incidence of Alzheimer's disease (AD). Additionally, accumulating evidence indicates that leptin has neuroprotective actions in various AD models, whereas dysfunctions in the leptin system accelerate AD pathogenesis. Here, we review the data implicating the leptin system as a potential novel target for AD, and the evidence that boosting the hippocampal actions of leptin may be beneficial. 
546 |a EN 
690 |a Leptin 
690 |a hippocampus 
690 |a synaptic plasticity 
690 |a tau 
690 |a AMPA 
690 |a Alzheimer's 
690 |a Medicine 
690 |a R 
690 |a Pharmacy and materia medica 
690 |a RS1-441 
655 7 |a article  |2 local 
786 0 |n Pharmaceuticals, Vol 14, Iss 1, p 52 (2021) 
787 0 |n https://www.mdpi.com/1424-8247/14/1/52 
787 0 |n https://doaj.org/toc/1424-8247 
856 4 1 |u https://doaj.org/article/3d7de7ffd6cc4e788a1fc6772e06a3b9  |z Connect to this object online.